Abstract
BACKGROUND: Enoxaparin is often diluted to accurately deliver doses to neonatal and infant patients. Current recommendations for dilutions may not be adequate for the smallest patients. METHODS: Review of dosing at our institution occurred, and an 8 mg/mL concentration of enoxaparin was chosen. A concentration of 8 mg/mL was compounded by diluting 0.4 mL of enoxaparin (100 mg/mL) into 4.6 mL of sterile water for injection into an empty sterile vial. Four syringes of the 8 mg/mL concentration were prepared by 5 technicians (20 total syringes). Stability and sterility testing occurred a 0, 7, 14, and 30 days. One-way repeated-measures analysis of variance was used to detect significant differences in Anti–Factor Xa concentrations at the testing time points. RESULTS: The dilution of enoxaparin was sterile at 30 days but exhibited significant degradation at the 30- day point (p < 0.05). CONCLUSION: A dilution of enoxaparin 8 mg/mL is stable and sterile for 14 days refrigerated but is not stable at 30 days.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 322-326 |
| Number of pages | 5 |
| Journal | Journal of Pediatric Pharmacology and Therapeutics |
| Volume | 21 |
| Issue number | 4 |
| DOIs | |
| State | Published - Jul 1 2016 |
Keywords
- Anti–factor xa concentrations
- Enoxaparin
- Low molecular weight heparin
- Neonates
- Stability
- Sterility
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
- Pharmacology (medical)
Fingerprint
Dive into the research topics of 'Stability and sterility of enoxaparin 8 mg/mL subcutaneous injectable solution'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS